| Vestibular Precision: Physiology & Pathophysiology (NCT04890132) | Massachusetts Eye and Ear Infirmary | 2020-07-01 |
| Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15 (NCT03893643) | Centre Hospitalier Universitaire de Nice | 2019-01-01 |
| Study of Aspirin in Patients With Vestibular Schwannoma (NCT03079999) | Massachusetts Eye and Ear Infirmary | 2018-06-11 |
| Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (NCT03095248) | Children's Hospital Medical Center, Cincinnati | 2017-05-08 |
| Reliability of Functional Outcome Measures in Neurofibromatosis 2 (NCT03617276) | Guy's and St Thomas' NHS Foundation Trust | 2016-09-07 |
| AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas (NCT02831257) | Massachusetts General Hospital | 2016-08-31 |
| Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype (NCT02298270) | Massachusetts General Hospital | 2014-03-01 |
| Neurofibromatosis (NF) Registry Portal (NCT01885767) | The Children's Tumor Foundation | 2012-06-01 |
| Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients (NCT01490476) | Assistance Publique - Hôpitaux de Paris | 2012-01-01 |
| Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors (NCT00973739) | NYU Langone Health | 2009-09-01 |
| PTC299 for Treatment of Neurofibromatosis Type 2 (NCT00911248) | PTC Therapeutics | 2009-07-31 |
| Concentration and Activity of Lapatinib in Vestibular Schwannomas (NCT00863122) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2009-06-01 |
| An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors (NCT00030043) | FDA Office of Orphan Products Development | 2001-09-01 |
| Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 (NCT00004437) | FDA Office of Orphan Products Development | 1999-10-01 |